Side-by-side comparison of AI visibility scores, market position, and capabilities
Curative is an AI-powered health insurance plan for employers that eliminates copays and deductibles; raised $153M Series B at $1B valuation; partners with employers to offer zero-cost primary and specialist care using a curated provider network.
Curative is a health insurance startup redesigning employer-sponsored health benefits by offering a plan that eliminates copays, deductibles, and coinsurance for employees who use Curative's curated network of primary care providers, specialists, and hospitals. Founded in 2020 in Austin, Texas by Fred Turner (who previously ran Curative's COVID testing business at massive scale), the company raised $153 million in a Series B round at a $1 billion valuation. Curative's model is built on the conviction that removing financial friction from healthcare access — specifically the upfront costs that deter people from seeking preventive and early care — ultimately reduces total healthcare spend for employers.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.